Newsquawk Logo

Eli Lilly's (LLY) triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

Newsquawk StaffPublished On the live feed at — 7 more headlines followed before this page went public
Newsquawk headlinesUTC

Kontoor Brands (KTB) to sell Lee for up to USD 1bln and expected to close in H2 '26

IBM (IBM) and the US Commerce Department announce the US's first purpose-built quantum foundry, supported by a proposed USD 1bln chips award

Eli Lilly's (LLY) triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

Russia's Kremlin says Ukraine was discussed with Chinese President Xi and they are ready to help efforts for peace; any nuclear exercises are a signal

Japanese trade union Rengo called Japan’s consumption tax an important source of social security funding and criticised allied parties’ proposals for consumption tax cuts, Nikkei reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
  • In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery
  • Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks
External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.